Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700683 · ClinicalTrials.gov registry record · NA
Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome
A NA study, sponsored by Noctrix Health.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT04700683: Completed NA study, sponsored by Noctrix Health.
NCT04700683 is a NA study that has completed, run by Noctrix Health. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04700683, a NA study, has completed, sponsored by Noctrix Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
Prospective multi-site randomized sham-controlled crossover feasibility study evaluating tolerability and efficacy of noninvasive peripheral nerve stimulation (NPNS) for patients with moderate-severe primary Restless Legs Syndrome (RLS). Response to NPNS investigational device was compared to sham control in a 2x2 crossover design such that subjects were assigned to receive 2 weeks of NPNS and 2 weeks of sham, in randomized order.
Primary Outcome
Subject satisfaction and usability questionnaire
Interventions
- DEVICE Noctrix Health NPNS device v1.0 - Active
- DEVICE Noctrix Health NPNS device v1.0 - Sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2019-07-14 |
| Est. Completion | 2020-03-01 |
| Phase | NA |
What the finished NCT04700683 record still lists
NCT04700683 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Noctrix Health NPNS device v1.0 - Active is the first listed.
NCT04700683 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04700683 about?
NCT04700683 is a clinical study titled "Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome". Prospective multi-site randomized sham-controlled crossover feasibility study evaluating tolerability and efficacy of noninvasive peripheral nerve stimulation (NPNS) for patients with moderate-severe primary Restless Legs Syndrome (RLS). Response to NPNS investigational device was compared to sham c...
What is the current status of trial NCT04700683?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2019-07-14. Estimated completion is 2020-03-01.
What interventions are being tested in trial NCT04700683?
The interventions under investigation include: Noctrix Health NPNS device v1.0 - Active (DEVICE), Noctrix Health NPNS device v1.0 - Sham (DEVICE).
Who is sponsoring clinical trial NCT04700683?
This trial is sponsored by Noctrix Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04700683's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI